Riskpilot← Back to searchSign inGet full accessFARMAGRUPPEN AS
ASActiveOrg 918570799Vettaliveien 4E, 0781 OsloActivities of employment placement agencies · NACE 7810Est. 20170 employees
Revenue 2024
NOK 705K
-49% vs 2023
EBITDA margin
20.1%
-68% vs 2023
Equity ratio
99.2%
Financial strength
Net profit 2024
NOK 1,4M
-35% vs 2023
| Revenue | NOK 705K | -49% |
| EBITDA | NOK 141K | -68% |
| Net profit | NOK 1,4M | -35% |
| Total assets | NOK 9,1M | +16% |
| Equity | NOK 9M | +19% |
| Employees | 0 | — |
Legal name
FARMAGRUPPEN AS
Org number
918570799
Legal form
Aksjeselskap
NACE code
7810 · Activities of employment placement agencies
Founded
1. mars 2017
Share capital
NOK 360 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg. Daglig leder alene. Styrets leder alene.
Company purpose
Formidle personal til bemanning av apotek, samt investering i aksjer, selskap og andre verdipapirer innen apotek bransjen og hva som naturlig faller sammen med dette.
Address
Vettaliveien 4E, 0781 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 628 | 2 545 | 3 288 | 1 386 | 705 |
| Staff expenses | −607 | −1 299 | −1 849 | −840 | −0 |
| EBITDA | −81 | 914 | 1 110 | 440 | 141 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −81 | 914 | 1 110 | 440 | 141 |
| Net financials | 509 | 623 | 396 | 1 890 | 1 327 |
| Profit before tax | 428 | 1 537 | 1 506 | 2 330 | 1 469 |
| Tax | −0 | 193 | 244 | 112 | 38 |
| Net profit | 428 | 1 344 | 1 262 | 2 218 | 1 431 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 059 | 4 565 | 5 705 | 7 793 | 9 062 |
| Equity | 1 985 | 4 079 | 5 341 | 7 559 | 8 990 |
| Long-term debt | 0 | 0 | 0 | 2 | 0 |
| Short-term debt | 74 | 486 | 364 | 232 | 72 |
| Total debt | 74 | 486 | 364 | 234 | 72 |
EBITDA margin
20.1%
This company
15.8%
Market median
+27% vs market
20202024
Equity ratio
99.2%
This company
38.2%
Market median
+160% vs market
20202024
Return on equity
15.9%
This company
18.4%
Market median
+14% vs market
20202024
Net profit margin
203.0%
This company
8.1%
Market median
+2406% vs market
20202024
Asset turnover
0.08×
This company
1.12×
Market median
-93% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AB Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (1) | ||
GA Chief Executive Officer | Chief Executive Officer | 2017 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2017 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33% | 33.33% | 2023 | |
| Company | 33.33% | 33.33% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Apoinvest Holding As
FARMAGRUPPEN AS Board members of FARMAGRUPPEN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Brekke | Chief Executive Officer | 0 companies |
| Gulzeb Aziz | Chief Executive Officer | 0 companies |
| Einar Mathias Teigen Rasch-Halvorsen | Chairman | 0 companies |